Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEan: SAR443122 in CLE
NCT04781816Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) comparing SAR443122 with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity Sub-Score at 12 weeks. Started Apr 2021; status: completed.
02
Drugs
eclitasertib
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT04781816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781816.